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SOX17 expression and its down-regulation by promoter methylation in cervical adenocarci-
noma in situ and adenocarcinoma
Aims: SOX17 expression has not been studied in
glandular lesions of the uterine cervix like adenocarci-
noma in situ (AIS) and invasive adenocarcinomas
(AdC), whereas SOX17 promoter CpG island methyla-
tion has been reported. Therefore, the aim of this study
was to relate the topographical distribution of SOX17
expression and SOX17 methylation status to each
other, and to SOX2 expression, human papillomavirus
(HPV) type, and physical status of the virus.
Methods and results: Immunohistochemistry was used
in 45 cases to assess expression of SOX17 and SOX2.
SOX17 promoter methylation was determined in 25
cases by means of bisulphite conversion and methyla-
tion-specific polymerase chain reaction. SOX17 and
SOX2 showed a mutually exclusive expression pattern
in normal epithelium, with a sharp delineation in the
squamocolumnar junction. SOX17 was found in endo-
cervical columnar and reserve cells, whereas SOX2
was exclusively found in squamous epithelium. In both
glandular lesions and cases with coexisting glandular
and squamous intraepithelial components, a complex
combination of SOX17 and SOX2 expression patterns
was seen and mutually exclusive expression was lost.
Frequently, gain of expression of SOX2 was found and
expression of SOX17 was lost. Methylation of the CpG
island in the SOX17 promoter was shown to be
strongly associated with loss of expression of SOX17
(P = 0.0016).
Conclusions: In this study, we show for the first time a
direct correlation between the topographical distribution
of SOX17 expression and the methylation status of its
gene promoter. This explains the heterogeneity of
SOX17 expression in the glandular lesions of the cervix.
No correlation was found between HPV type and physi-
cal status of the virus on the one hand and methylation
status on the other.
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Introduction
Cervical cancer is the fourth most frequent cancer in
women, with an estimated 570 000 new cases in
2018. Approximately 90% of deaths from cervical
cancer occurred in low-income and middle-income
countries.1 Human papillomavirus (HPV) has been
identified as a definite human carcinogen for six types
of cancer, i.e. cancers of the cervix, penis, vulva,
vagina, anus, and oropharynx (including the base of
the tongue and tonsils).2,3 Cervical cancer originates
in the transformation zone of the uterine cervix
through HPV infection. In this dynamic area, prema-
lignant lesions originate and endocervical columnar
cells are replaced by squamous epithelium. The
squamocolumnar junction (SqCJ) is the landmark
between these two epithelial tissue types.4–9 There is
a general consensus that reserve cells can be
regarded as a progenitor cell population capable of
generating squamous-type epithelium,9 but can also
differentiate into columnar cells, thereby replenishing
the endocervical glandular epithelium.5,10–13 How-
ever, direct evidence for this type of cell being a pro-
genitor for normal columnar epithelium is still
lacking. Recently, Mockler et al., using keratin 17
(K17) immunohistochemistry, showed a phenotypic
correlation between these subcolumnar reserve cells
and glandular neoplasia.
They reported that K17 was not found in the
epithelial cells of benign glandular lesions, but rather
in groups of cuboidal cells residing beneath the epithe-
lial layer of these lesions. The majority of endocervical
adenocarcinoma (AdC) and AdC in situ (AIS) is K17-
positive, suggesting a role for these cells in the devel-
opment of such endocervical (pre)malignancies.14,15
Both squamous and glandular carcinomas develop
in the cervical transformation zone which is an
important argument for the hypothesis that the
reserve cells play a central role in the pathogenesis of
both squamous and glandular cervical lesions.16–21
The majority of cervical cancers are represented by
squamous cell carcinomas (SCCs) (~80%) and AdCs
(~20%), developing through their respective premalig-
nant lesions, i.e. squamous intraepithelial lesion (SIL)
and AIS. Coexistence of SIL and AIS can be found in
the same specimen.13,19
Viral integration has been reported as an early
event in AIS formation, as opposed to SIL, in which
precancerous lesions showed exclusively episomal
viral genomes, and a minority of the carcinomas had
integrated viral genomes.16,22,23
HPV16, HPV18 and HPV45 were found substan-
tially more often in the integrated state than HPV31
and HPV33. HPV promotes cellular proliferation and
abrogates cell cycle checkpoints involving p53 and
retinoblastoma protein (pRb). These proteins are dereg-
ulated by the viral E6 and E7 proteins, and viral inte-
gration results in constant expression of these proteins.
This is a result of the inactivation of the viral E2 pro-
tein by its deletion, which leads to enhancement of E6
and E7 expression, influencing tumour progression.2
In the current study, we immunohistochemically
examined the expression pattern of the transcription
regulator protein SRY-box containing gene 17
(SOX17) in normal cervical glandular epithelium and
in the lesions derived therefrom. Only HPV-associated
glandular lesions were studied.
SOX17 is known to play a pivotal role in human
development,24,25 but so far its distribution in the uter-
ine cervix has not been studied. The promoter CpG
island region of SOX17 has been reported to be methy-
lated in the majority of squamous and glandular (pre)-
malignant lesions of the uterine cervix.26 As a single
marker, promoter CpG island methylation of SOX17
has been shown to be associated with progression of
high-grade SIL (HSIL) into carcinoma.27 Another tran-
scription regulator protein from the SRY-box gene fam-
ily, SOX2, has been shown to play an important role
during the progression of SIL lesions. The expression
level increased with severity of the SIL lesion.28,29 This
marker has not yet been studied in AIS and AdC.
Recently, growing evidence has indicated that
SOX17 plays an important role in human carcino-
genesis. Down-regulation of SOX17 expression has
been detected in colorectal cancer, hepatocellular car-
cinoma, gastric cancer, lung and oesophageal carci-
noma, among others.30–32 Hypermethylation of the
SOX17 promoter correlates with a poor prognosis for
several cancers, and provides important prognostic
information in breast cancer patients.32 Recent stud-
ies have shown that SOX17 is also epigenetically
silenced in circulating tumour cells isolated from the
peripheral blood of patients with breast or gastric
cancer, and can be used as a molecular diagnostic
marker in early-stage gastric cancer.32
In the current study, we therefore also examined the
role of SOX17 promoter CpG island methylation in the
development of glandular lesions of the uterine cervix.
SOX2 expression, HPV typing of the lesions, chro-
mogenic in-situ hybridisation (CISH) and several
molecular markers were used for correlation with
SOX17 expression and SOX17 promoter methylation.
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Materials and methods
T I S S U E S
The following types of tissue sample were selected
from the archives of the Departments of Pathology of
the Foundation of Collaborating Hospitals in Eastern
Groningen, Pathan Rotterdam and the Reinier de
Graaf Hospital Delft, The Netherlands:
1. Formalin-fixed paraffin-embedded (FFPE) tissues
from 12 normal cervices removed for non-cervix-
related conditions during hysterectomy of pre-
menopausal women. In 11 of the 12 samples,
reserve cells could be found. There was no previ-
ous history of cervical abnormalities.
2. FFPE tissues from representative samples of cervi-
cal (pre)neoplastic lesions were selected, including
23 AIS cases. In 10 of these AIS cases, a coexist-
ing SIL was recognised; two were low-grade SIL
(LSIL) and eight were HSIL. Furthermore, 22
endocervical AdCs were examined. For compar-
ison, nine LSIL cases, 23 HSIL cases and 20 SCC
cases were also included. Sections were re-evalu-
ated by two pathologists, who selected representa-
tive tissue blocks in each case. Regions with
microglandular hyperplasia were occasionally
found in these samples. In all of these cases,
SOX17 expression was assessed with immunohis-
tochemistry, and 11 solitary AISs, five lesions with
coexisting AIS and SIL components, nine AdCs,
eight LSILs and 10 HSILs were also tested for
methylation of SOX17. These were all analysed for
HPV, and selected cases were additionally
immunostained for several differentiation markers.
Research on tumour samples was performed
according to the Code for Proper Secondary Use of
Human Tissue in The Netherlands (http://www.fede
ra.org/, update 2011), and was approved by the Med-
ical Ethics Committees of the Erasmus University
Medical Centre, Rotterdam and of the Foundation of
Collaborating Hospitals of Eastern Groningen, The
Netherlands.
I M M U N O H I S T O C H E M I S T R Y
Immunohistochemical staining on 4-µm-thick FFPE
tissue sections was performed with primary antibodies
against SOX17, SOX2, K17, Ki67, and p16. Detailed
information on antibodies and assay conditions is
given in Table S1 in Data S1. The sections were
scanned with a Ventana iScan HT slide scanner (Ven-
tana Medical Systems, Tucson, AZ, USA), and semi-
quantitatively scored for expression of SOX17, SOX2,
K17, Ki67, and p16. Images were viewed and
selected with IMAGE VIEWER Software (Ventana Medical
Systems).
H P V
HPV genotyping was performed with the multiplex
ligation-dependent probe amplification assay or the
Single tube Multiplex Amplification in Real Time kit
(PathoFinder, Maastricht, The Netherlands).33,34 HPV
typing was performed on DNA isolated from
4-µm-thick FFPE tissue sections or DNA isolated from
cytological samples matched with the tissue obtained
after colposcopy and processed for histological exami-
nation.
H P V I N - S I T U H Y B R I D I S A T I O N ( I S H )
HPV was detected by means of CISH, with DNA
probes for HPV16, HPV18, HPV31, and HPV45. For
a detailed description of HPV ISH, see Data S1. The
CISH signals were classified according to their distri-
bution patterns, which were typical for the presence
of episomal viral copies, viral replication, or viral inte-
gration into the human genome.35
S O X 1 7 P R O M O T E R C P G I S L A N D M E T H Y L A T I O N
DNA was isolated from cells from FFPE sections by
means of manual dissection. The areas for isolation
were selected on the basis of p16 and SOX17
immunostaining, or ISH HPV positivity (Data S1).
DNA was bisulphite-treated (EZ DNA Methylation-
Direct Kit; Zymo Research, Irvine, CA, USA), and,
after conversion, the potentially methylated SOX17
DNA was amplified. Subsequently, polymerase chain
reaction with specific primers for the methylated CpG
island and unmethylated CpG island was performed
(Table S2 in Data S1).36,37 To compare the methyla-
tion status with the immunohistochemical expression
of SOX17, Fisher’s exact test was used to test the sta-
tistical significance.
Results
E X P R E S S I O N P A T T E R N S O F S O X 1 7 I N T H E N O R M A L
A D U L T C E R V I X
In samples of the normal adult cervix, the abrupt
mucosal transition between the squamous epithelium
and the endocervical epithelium the SqCJ was charac-
terised by the exclusive expression of SOX17 in the
glandular (columnar) epithelium (Figure 1A) and its
© 2019 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
SOX17 expression and methylation in cervical AIS 3
absence in the normal ectocervical squamous epithe-
lium (Figure 1B). SOX17 was also extensively
expressed in the reserve cells underlying the colum-
nar epithelium (Figure 1E). SOX17 was occasionally
found in the cases with mature squamous metaplasia
(result not shown). SOX2 expression is, in general, an
indicator of squamous differentiation, and was there-
fore used to immunophenotype these cell types in the
normal cervix. A mutually exclusive staining pattern
of SOX2 and SOX17 was seen, with mainly the basal
and suprabasal layers of the squamous epithelium
being positive for SOX2, and no reactivity in the
glandular component (compare Figure 1C,D). Reserve
cell SOX2 expression could not be found (Figure 1F).
E X P R E S S I O N P A T T E R N S O F S O X 1 7 I N G L A N D U L A R
( P R E ) M A L I G N A N T L E S I O N S
The expression patterns of SOX17 and SOX2 were
semiquantitatively assessed in total 35 glandular
lesions (AIS and AdC), and 10 lesions with coexisting
AIS and SIL components (Table 1). For comparative
reasons, in total 52 squamous lesions, like LSIL, HSIL
and SCC, were also analysed (results not shown).
Many of the endocervical glandular (pre)malignant
lesions, which were expected to express exclusively
SOX17 (see, for example, Figure 2A,B), on the basis
of the above-described results for the normal cervical
epithelium, showed coexpression of SOX17 and SOX2
(Figure 2E,F), or even exclusive expression of SOX2
(Figure 2C,D). In 21 of 35 solitary AISs and AdCs,
SOX17 expression was evident, and in 18 of these
lesions SOX2 expression was found. In four cases,
both SOX17 and SOX2 were expressed to a compara-








epithelium. SOX17 staining (A,
B,E) and SOX2 staining (C,D,F)
in corresponding areas show
SOX17 positivity and SOX2
negativity in the normal
glandular invaginations (A,C),
and the opposite staining
pattern in mature squamous
epithelium (B,D). The reserve
cells underlying the glandular
epithelium are only SOX17-
positive (E,F).
Table 1. Overview of SOX17 and SOX2 expression pat-












6 5 2 0
Coexisting AIS and SIL (n = 10)
AIS 5 1 3 1
SIL 2 7 1 0
Adenocarcinomas
(n = 22)
6 4 7 5
AIS, Adenocarcinoma in situ; SIL, Squamous intraepithelial lesion.
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K17-positive reserve cells were found in small areas
of AIS lesions, and showed strong nuclear SOX17
positivity and no Ki67 staining (Figure 2G–I).
In lesions with coexisting glandular and squamous
premalignant components (AIS/SIL; Figure 3), the
glandular component in eight of 10 synchronous
lesions expressed predominantly SOX17 (Figure 3B),
whereas the squamous component exclusively
expressed SOX2 in seven of the 10 cases (Figure 3C).
One case was negative for both, and two SIL lesions
showed predominant SOX17 expression. In all of
these cases, HPV could be found (Table 2, coexisting
cases), with two cases showing viral replication in
the SIL component, and the AIS component showing
the virus to be integrated (Figure 3D,E).
For reference purposes, SIL lesions and cervical
SCCs were also immunostained for SOX17 and SOX2.
Exclusive SOX2 positivity or predominant expression
of SOX2 was seen in 27 of the 32 SIL lesions (LSIL
and HSIL), and only two cases showed predominant
or exclusive expression of SOX17. Coexpression of
SOX17 with SOX2 was found in six of 32 cases. All
20 SCCs showed exclusive SOX2 expression in 30–
100% of the cells (results not shown).
P R O M O T E R C P G I S L A N D M E T H Y L A T I O N I S
A S S O C I A T E D W I T H D O W N - R E G U L A T I O N O F S O X 1 7
E X P R E S S I O N I N G L A N D U L A R L E S I O N S
To explain the unexpected loss of SOX17 expression
in the AISs and AdCs, the promoter CpG island
methylation status of SOX17 in these lesions was
determined. In both AIS and AdC methylation of this






Figure 2. Examples of the
three different combinations of
SOX17 and SOX2 expression
patterns found in solitary
adenocarcinoma in situ (AIS).
A,B, Only strong nuclear
SOX17 positivity and SOX2
negativity (a few nuclei stained
weakly for SOX2). C,D, Only
strong nuclear SOX2 positivity
and nuclear negativity for
SOX17. E,F, Strong
simultaneous expression of
SOX2 and SOX17. G,H,I, High
reserve cell density (SOX17
and keratin 17 positivity, and
Ki67 negativity) in close
proximity to AIS.
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regulation of SOX17 expression at the protein level
(Table 2). In 10 cases, methylation could be found
when SOX17 was not expressed, whereas, in seven
cases, SOX17-positive areas were non-methylated. In
three of these cases, an abrupt change in SOX17
immunostaining was seen in adjacent regions within
the same lesion. In two of these cases (cases 6 and 7
in Table 2), the methylation status could be analysed
(see Figure 4A–C for illustration of case 6), and
showed the association between SOX17 expression
and SOX17 methylation status. Fisher’s exact test
was used to test the statistical significance; a P-value
of 0.0016 was determined for the association
between non-methylated CpG islands in the promoter
region of SOX17 and expression of SOX17 versus pro-
moter methylation and loss of expression of SOX17 in
glandular preneoplasia in a total of 32 analysed
areas. In the lesions with coexisting AIS and SIL com-
ponents (cases 12–16 in Table 2), the association
between methylation status and expression of SOX17
was confirmed in all samples (see also Figure 4C–E).
In normal squamous epithelium, used as a control,
the examined CpG island in the promoter region of
SOX17 was methylated in only one of 15 samples
examined, whereas, in six of 18 SIL cases,
methylation of SOX17 was found, mostly in HSIL (re-
sults not shown).
C I S H
Table 2 provides an overview of HPV type and physi-
cal status of the virus. Thirteen cases were HPV16-
positive, 10 cases were HPV18-positive (eight could
be analysed with CISH), and two cases were HPV45-
positive. HPV16 was found to be integrated in nine of
13 (AIS and AdC) lesions, and HPV18 was found to
be integrated in seven of eight cases. HPV45 was
integrated in one case. Among the lesions with coex-
isting AIS and SIL components, all cases showed epi-
somal copies, whereas, in four of five AIS cases, the
virus was shown to be integrated. We noted that four
of seven and two of nine cases showed combined
methylation of SOX17 and viral integration for,
respectively, HPV18 and HPV16.
Discussion
The two major types of premalignant cervical lesion




Figure 3. Example of a
premalignant lesion with
coexisting glandular and
squamous components. A, Low
magnification of a lesion with
coexisting adenocarcinoma
in situ (AIS) and squamous
intraepithelial lesion (SIL)
components immunostained
for p16 (case 13). B, Glandular
component expressing SOX17.
C, Squamous component




HPV16 integration in the AIS
component (D) and replication
of the virus in the low-grade
SIL component (E).
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with combined AIS/SIL lesions, which represents
~20% of cases. The transformation zone between the
glandular epithelium and the squamous epithelium
of the cervix has been described as a high-risk
region for the development of these lesions.8,9,11,12,38
We have now shown that the mutually exclusive
expression patterns of the transcription factors
SOX17 and SOX2 mark the SqCJ in the normal
transformation zone of the adult cervix. Their speci-
fic immunostaining patterns distinguish between the
SOX2-positive squamous epithelium on the one
hand, and the SOX17-positive endocervical glandu-
lar epithelium on the other. Reserve cells were
shown to express SOX17 but not SOX2. The fact
that columnar and reserve cells share SOX17
expression suggests that the latter can act as the
progenitor cells of endocervical columnar epithelium.
It could also be an equally strong argument for the
concept that columnar cells are progenitors of the
reserve cells, as suggested by Crum et al.39; such a
transition has also been shown to occur during
human embryogenesis.40
Table 2. Overview of SOX17 and SOX2 expression in relation to SOX17 methylation status, human papillomavirus (HPV)
type in glandular lesions, and physical status of the virus
: No immunostaining, no methylation.
: Positive nuclear immunostaining, methylation.
: Faint immunostaining, small fraction of methylated cells.
: Two concurrent areas analysed.
/ : AIS and SIL separately analysed.
AdC, Adenocarcinoma; AIS, Adenocarcinoma in situ; CISH, Chromogenic in-situ hybridisation; IHC, Immunohistochemical staining result;
NA, Not available/not suitable for analysis; SIL, Squamous intraepithelial lesion; SqE, Squamous epithelium.
IHC SOX17 methylation HPV CISH


















12 / / n.a 18 / /
13 / / / 16 / /
14 / / / n.a 16 / /
15 / / / 16 / /
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On the basis of the SOX expression patterns seen in
normal endocervical columnar cells and in reserve
cells, we expected that AIS and AdC would exclu-
sively express SOX17. Indeed, approximately half of
the glandular lesions expressed SOX17, whilst the
other half were SOX17-negative, matching perfectly
with SOX17 promoter methylation.
Earlier studies have found the promoter CpG island
region of SOX17 to be methylated in the majority of
squamous and glandular lesions of the uterine cer-
vix,26 and this was also shown to be associated with
progression of HSIL to carcinoma.27 In the current
study, we directly correlated the topographical
SOX17 distribution pattern, as determined with
immunohistochemistry, with epigenetic changes, i.e.
methylation of the SOX17 promoter region. This
combination of techniques allows us to draw some
specific conclusions. For example, in individual cases,
abrupt loss of SOX17 as seen in adjacent AIS regions
suggests that the lesion progresses from an unmethy-
lated SOX17 status to a methylated SOX17 status.
However, we observed no significant correlation
between progression of AIS to AdC and down-regula-
tion of SOX17 expression.
At the molecular level, the epigenetic silencing of
SOX17 has been correlated with activation of the
Wnt signalling pathway. Sinner et al.41 and Jia
et al.31 have shown that SOX17 promotes the degra-
dation of b-catenin–T-cell factor (TCF) via a glycogen
synthase kinase-3b-independent mechanism, and Van
der Meide et al.26 have suggested that there is direct
inhibition of b-catenin–TCF–lymphoid enhancer fac-
tor function by SOX17. Recently, Li et al.42 also
demonstrated that SOX17 restrains proliferation and
tumour formation in squamous cervical cancer by
down-regulating the activity of the Wnt–b-catenin
signalling pathway via trans-suppression of b-catenin.
Therefore, down-regulation of SOX17 expression by
promoter methylation can result in activation of the
Wnt signalling pathway, stimulating the proliferation
and genetic instability of premalignant lesions. This
also suggests that, in SOX17-positive regions of AIS,
alternative pathways induce proliferation.
The evident pathway that promotes cellular prolif-
eration and abrogates cell cycle checkpoints involves
p53 and pRb via HPV. These proteins are deregulated
by the viral E6 and E7 proteins. Viral integration into
the human genome results in constant expression of
Area
1 2 3 4 5 6





Figure 4. Examples of
methylation analyses of SOX17
in a solitary adenocarcinoma
in situ (AIS) and a lesion with
coexisting AIS and squamous
intraepithelial lesion (SIL)
components. A,B, Solitary AIS
(case 6). D,E, Lesion with
coexisting AIS and SIL
components (case 13). (A) and
(E) show SOX17
immunohistochemical staining
of these lesions. Tissue was
isolated by means of manual
scraping (B,D). DNA was
isolated from two dysplastic
areas within AIS case 6 (area
2, SOX17-positive; area 3,
SOX17-negative) and from two
areas within AIS/SIL case 13
(area 4, AIS SOX17-positive;
area 5, high-grade SIL SOX17-
negative). C, Methylation
status of SOX17 in the
different areas with an internal
positive DNA control (HeLa) in
lane 6. U, unmethylated CpG
island; M, methylated CpG
island.
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these proteins, as the E2 protein is inactive because
of deletion. As a result, E6 expression and E7 expres-
sion are promoted, which subsequently promotes the
development of the neoplastic lesion.2
Statistical analysis did not reveal a significant asso-
ciation between the SOX17 methylation status of the
lesions and viral integration. Viral integration has
been reported for HPV18 in adenomatous lesions, as
confirmed in our study, and HPV16 was integrated
in more than half of the lesions.22,43
We can only conclude that SOX17 methylation
and viral integration, although frequently detected
simultaneously in glandular lesions, are independent
processes. Also, no direct interaction between viral
proteins and SOX17 promoter regions or transcription
regulator proteins has been reported so far.
The expression of SOX2 in a major proportion of
the solitary AIS and AdC cases was unexpected. This
may be a reflection of the bidirectional differentiation
properties of the reserve cell. Furthermore, the expres-
sion of SOX2 also supports our earlier findings19 that
solitary AIS can express markers of squamoid differ-
entiation such as keratin 5 and p63 or could be the
result of the gain of chromosome 3q harbouring the
SOX2 gene.44,45 AIS has been reported to be associ-
ated with SIL in 25–75% of cases.13,16,19,46 The con-
currence of both types of lesion in the same biopsy
supports the hypothesis that both lesions may arise
from a single progenitor cell or area at risk. Reserve
cells, which are capable of undergoing both columnar
and squamous differentiation, may be candidate pro-
genitor cells for the formation of these combined
lesions.10,19,39 This view is supported by the observa-
tion that, in incidental cases of lesions with coexisting
AIS and SIL, K17-positive reserve cells were found to
be p16-positive and HPV-positive.10
In conclusion, this study shows, for the first time, a
direct correlation between the topographical distribu-
tion of SOX17 expression and the methylation status
of its gene promoter region. This combination of tech-
niques has clearly shown the heterogeneity of SOX17
expression in the glandular lesions of the cervix, an
observation that could not be made on the sole basis
of the methylation studies performed so far.
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